RxDoctor Payments Data

Gina Owens

Family · Murray, KYNPI 1982124491

Payments from drug & device makers

$2,581in general payments, 2019–2025

Across 160 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$347
  • Lilly USA, LLC$308
  • Amgen$254
  • Lundbeck LLC$222
  • AstraZeneca$203
  • Bayer$192
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,53698%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,581 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$66,129
Medicare patients
257
Services billed
2,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol64$59,712
OzempicSemaglutide24$33,688
MounjaroTirzepatide23$27,094
Tresiba Flextouch U-200Insulin Degludec12$17,969
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$14,616
JardianceEmpagliflozin11$14,374
EliquisApixaban16$14,031
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$13,296
Lagevrio (Eua)Molnupiravir12$7,211
Albuterol Sulfate HfaAlbuterol Sulfate177$4,678
Venlafaxine Hcl ErVenlafaxine Hcl13$2,830
Bumetanide35$1,817
Atorvastatin Calcium205$1,690
Fluticasone Propionate93$1,489
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$1,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$203$73,00879 claims
Novo NordiskOzempic$188$33,68824 claims
Boehringer IngelheimStiolto Respimat, Jardiance$45$28,99023 claims
Lilly USA, LLCMounjaro$308$27,09423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Murray

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →